[{"address1": "2625 Townsgate Road", "address2": "Suite 230", "city": "Westlake Village", "state": "CA", "zip": "91361", "country": "United States", "phone": "805 267 9889", "website": "https://www.genelux.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.", "fullTimeEmployees": 23, "auditRisk": 9, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 4, "previousClose": 2.28, "open": 2.31, "dayLow": 2.06, "dayHigh": 2.3568, "regularMarketPreviousClose": 2.28, "regularMarketOpen": 2.31, "regularMarketDayLow": 2.06, "regularMarketDayHigh": 2.3568, "forwardPE": -1.9074073, "volume": 223319, "regularMarketVolume": 223319, "averageVolume": 226630, "averageVolume10days": 156960, "averageDailyVolume10Day": 156960, "bid": 2.04, "ask": 2.12, "bidSize": 300, "askSize": 100, "marketCap": 70765120, "fiftyTwoWeekLow": 2.06, "fiftyTwoWeekHigh": 35.15, "priceToSalesTrailing12Months": 8845.64, "fiftyDayAverage": 3.2925, "twoHundredDayAverage": 10.9523, "currency": "USD", "enterpriseValue": 37464620, "floatShares": 21477046, "sharesOutstanding": 34352000, "sharesShort": 2441940, "sharesShortPriorMonth": 2034212, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.090500005, "heldPercentInsiders": 0.17534, "heldPercentInstitutions": 0.17683001, "shortRatio": 17.84, "shortPercentOfFloat": 0.1126, "impliedSharesOutstanding": 35865300, "bookValue": 0.568, "priceToBook": 3.6267602, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -25783000, "trailingEps": -0.92, "forwardEps": -1.08, "enterpriseToRevenue": 4683.077, "enterpriseToEbitda": -1.477, "52WeekChange": -0.928223, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GNLX", "underlyingSymbol": "GNLX", "shortName": "Genelux Corporation", "longName": "Genelux Corporation", "firstTradeDateEpochUtc": 1674743400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "818a2610-5027-31af-b56b-57304f2478db", "messageBoardId": "finmb_11172383", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.06, "targetHighPrice": 32.0, "targetLowPrice": 18.0, "targetMeanPrice": 23.5, "targetMedianPrice": 22.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 19627000, "totalCashPerShare": 0.739, "ebitda": -25371000, "totalDebt": 2371000, "quickRatio": 2.515, "currentRatio": 2.717, "totalRevenue": 8000, "debtToEquity": 15.719, "returnOnAssets": -0.82135004, "returnOnEquity": -2.90104, "freeCashflow": -11130000, "operatingCashflow": -20039000, "revenueGrowth": -0.953, "grossMargins": 1.0, "operatingMargins": -1014.375, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]